Pfizer Inc. and French vaccine maker Valneva announced the topline results of their Phase 3 VALOR trial for the Lyme disease vaccine candidate PF‑07307405 (VLA15). The study enrolled 9,400 participants aged five and older and reported a 73.2% efficacy rate 28 days after the fourth dose, with a 74.8% efficacy rate from one day after the fourth dose. The efficacy exceeded the 70% threshold set by investigators but the trial did not meet its primary statistical endpoint because the lower bound of the 95% confidence interval fell below the pre‑specified target of 20, a shortfall attributed to fewer Lyme disease cases than expected during the enrollment period. The vaccine, a 6‑valent OspA‑based candidate, was well tolerated with no safety concerns reported.
The results represent a clinically meaningful benefit in a population that currently has no approved human Lyme disease vaccine. Pfizer and Valneva view the data as a strong foundation for regulatory submissions to the FDA and EMA in 2026. The partnership, which began in 2020, gives Pfizer control of commercialization while Valneva receives a $130 million upfront payment and is eligible for milestone payments and royalties. Valneva estimates peak annual sales of about $1 billion, a figure that reflects the large U.S. market of roughly 476,000 diagnosed cases per year and the broader global opportunity.
Despite the positive efficacy, the market reaction was muted. Valneva’s shares fell as much as 29% on the news, driven by investor concern that the missed primary endpoint could delay regulatory approval and raise questions about commercial viability. Analysts noted that the historical precedent of LYMERix—approved in 1998 and voluntarily discontinued in 2002 due to weak demand and safety concerns—adds caution to the outlook.
The trial also faced operational setbacks: in 2023, some sites failed to meet Good Clinical Practice standards, leading to the discontinuation of about 50% of U.S. patients. This issue, combined with the lower case accrual, contributed to the statistical shortfall.
Pfizer’s senior vice president of vaccines, Annaliesa Anderson, emphasized that the efficacy “is highly encouraging and creates confidence in the vaccine’s potential to protect against this debilitating disease.” Valneva’s CEO Thomas Lingelbach added that the results bring the company closer to delivering a needed vaccine and that they are grateful for Pfizer’s commitment.
The data underscore the unmet medical need for a Lyme disease vaccine and the potential for a first‑to‑market product, but the missed endpoint and market skepticism highlight the challenges of translating clinical success into regulatory approval and commercial success.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.